TY - JOUR
T1 - Global prevalence of insulin resistance in the adult population
T2 - a systematic review and meta-analysis
AU - Ballena-Caicedo, Jhosmer
AU - Zuzunaga-Montoya, Fiorella E.
AU - Loayza-Castro, Joan A.
AU - Bustamante-Rodríguez, Juan Carlos
AU - Vásquez Romero, Luisa Erika Milagros
AU - Tapia-Limonchi, Rafael
AU - De Carrillo, Carmen Inés Gutierrez
AU - Vera-Ponce, Víctor Juan
N1 - Publisher Copyright:
Copyright © 2025 Ballena-Caicedo, Zuzunaga-Montoya, Loayza-Castro, Bustamante-Rodríguez, Vásquez Romero, Tapia-Limonchi, De Carrillo and Vera-Ponce.
PY - 2025
Y1 - 2025
N2 - Objective: To determine the global prevalence of IR, evaluating differences according to study designs and population characteristics. Methodology: A systematic review with meta-analysis was conducted. The search encompassed MEDLINE (PubMed), Scopus, Web of Science, and EMBASE, including observational studies that employed the HOMA-IR index to estimate IR and published adult prevalence data. Articles without clear IR definitions or with highly specific populations were excluded. The meta-analysis applied a random-effects model with proportion transformation (Freeman-Tukey), assessing heterogeneity with I² and Cochran’s Q test. Additionally, a meta-regression by publication year was conducted. Results: Eighty-seven studies were included, with 235,148 participants. The pooled prevalence of IR was estimated at 26.53% (95% CI: 24.10–29.03; I²=99%), with no statistically significant differences when comparing probabilistic versus non-probabilistic sampling or when stratifying by sex. The meta-regression revealed no clear variations according to publication year or other explored factors. Conclusions: This systematic review demonstrates that IR reaches a global prevalence of 26.53%, with estimated differences between 26% and 30% across different populations and geographical regions. Despite the diversity in cut-off points employed for HOMA-IR, no statistically significant differences were observed when comparing sampling designs or stratifying by sex. Furthermore, no clear trend related to publication year was evidenced.
AB - Objective: To determine the global prevalence of IR, evaluating differences according to study designs and population characteristics. Methodology: A systematic review with meta-analysis was conducted. The search encompassed MEDLINE (PubMed), Scopus, Web of Science, and EMBASE, including observational studies that employed the HOMA-IR index to estimate IR and published adult prevalence data. Articles without clear IR definitions or with highly specific populations were excluded. The meta-analysis applied a random-effects model with proportion transformation (Freeman-Tukey), assessing heterogeneity with I² and Cochran’s Q test. Additionally, a meta-regression by publication year was conducted. Results: Eighty-seven studies were included, with 235,148 participants. The pooled prevalence of IR was estimated at 26.53% (95% CI: 24.10–29.03; I²=99%), with no statistically significant differences when comparing probabilistic versus non-probabilistic sampling or when stratifying by sex. The meta-regression revealed no clear variations according to publication year or other explored factors. Conclusions: This systematic review demonstrates that IR reaches a global prevalence of 26.53%, with estimated differences between 26% and 30% across different populations and geographical regions. Despite the diversity in cut-off points employed for HOMA-IR, no statistically significant differences were observed when comparing sampling designs or stratifying by sex. Furthermore, no clear trend related to publication year was evidenced.
KW - insulin resistance
KW - meta-analysis
KW - prevalence
KW - public health
KW - systematic review
UR - https://www.scopus.com/pages/publications/105015579705
U2 - 10.3389/fendo.2025.1646258
DO - 10.3389/fendo.2025.1646258
M3 - Review article
AN - SCOPUS:105015579705
SN - 1664-2392
VL - 16
JO - Frontiers in Endocrinology
JF - Frontiers in Endocrinology
M1 - 1646258
ER -